NARS1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: HEPG2 and A172 cell lysates, Primary antibody: P09928(NARS1 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09928(NARS1 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

The NARS1 antibody targets the enzyme asparaginyl-tRNA synthetase (NARS), encoded by the *NARS1* gene. This cytoplasmic enzyme is a member of the aminoacyl-tRNA synthetase (AARS) family, which plays a critical role in protein synthesis by catalyzing the attachment of asparagine to its cognate tRNA. NARS1 ensures translational fidelity and is essential for cellular function, particularly in tissues with high metabolic demands. Dysregulation or mutations in *NARS1* have been linked to neurodevelopmental disorders, including microcephaly, intellectual disability, and early-onset epilepsy, highlighting its importance in brain development.

NARS1 antibodies are widely used in research to study protein expression, subcellular localization, and molecular mechanisms in diseases. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Commercially available NARS1 antibodies are typically developed in hosts such as rabbits or mice, with validation in specific experimental models. Recent studies also explore NARS1’s potential role beyond translation, including interactions in stress responses or signaling pathways.

These antibodies are crucial for investigating pathogenic variants in *NARS1*-related disorders and for developing diagnostic or therapeutic strategies. Researchers rely on their specificity to dissect NARS1’s functional contributions in both physiological and pathological contexts.